Ligand Pharmaceuticals (LGND) Interest Expenses (2010 - 2026)
Ligand Pharmaceuticals (LGND) posted Interest Expenses of $14.9 million for Q1 2026, up 67627.27% sequentially from $22000.0 in Q4 2025, and up 1618.57% YoY from $867000.0 in Q1 2025.
Ligand Pharmaceuticals (LGND) Interest Expenses (2010 - 2026) Analysis & Trends
Ligand Pharmaceuticals has reported Interest Expenses for 17 years, with the latest figure at $14.9 million in Q1 2026.
- Quarterly Interest Expenses rose 1618.57% year-over-year to $14.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.9 million (up 163.67% YoY) and the FY2025 annual result came in at $31.7 million, down 55.74% from the prior year.
- Interest Expenses advanced to $14.9 million in Q1 2026 per LGND's latest filing, from $22000.0 in the prior quarter.
- Over five years, Interest Expenses peaked at $14.9 million in Q3 2025 and troughed at $1000.0 in Q3 2023.
- A 5-year average of $2.5 million and a median of $741000.0 in 2024 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2023 and 2024: Interest Expenses sank 99.7% in 2023, then soared 74000.0% in 2024.
- Over 5 years, Interest Expenses stood at $240000.0 in 2022, then soared by 363.33% to $1.1 million in 2023, then jumped by 149.55% to $2.8 million in 2024, then plunged by 99.21% to $22000.0 in 2025, then surged by 67627.27% to $14.9 million in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $14.9 million, $22000.0, and $14.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Ligand Pharmaceuticals | 5.87 Bn | 4.51 Bn | 60.48 Mn | 33.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 33.41 Mn |
| Jun 30, 2026 | 33.41 Mn |
| Mar 31, 2026 | 14.90 Mn |
| Mar 31, 2026 | 14.90 Mn |
| Dec 31, 2025 | 22,000.00 |
| Dec 31, 2025 | 22,000.00 |
| Sep 30, 2025 | 14.90 Mn |
| Sep 30, 2025 | 14.90 Mn |
| Jun 30, 2025 | 104,000.00 |
| Jun 30, 2025 | 104,000.00 |
| Mar 31, 2025 | 867,000.00 |
| Mar 31, 2025 | 867,000.00 |
| Dec 31, 2024 | 2.78 Mn |
| Dec 31, 2024 | 2.78 Mn |
| Sep 30, 2024 | 741,000.00 |
| Sep 30, 2024 | 741,000.00 |
| Jun 30, 2024 | 1.27 Mn |
| Jun 30, 2024 | 1.27 Mn |
| Mar 31, 2024 | 141,000.00 |
| Mar 31, 2024 | 141,000.00 |